



COMPREHENSIVE WORK-UP FOR ACUTE OPHTHALMOPARESIS WITH ELEVATED GQ1B ANTIBODIES IS WARRANTED IN TIMES OF THE PANDEMIC

Finsterer J, MD, PhD [1]

[1] Klinik Landstrasse, Messerli Institute, Vienna, Austria

Key words: Miller-Fisher syndrome, GQ1b, steroids, immune-mediated, SARS-CoV-2

Corresponding author: **Finsterer J, MD, PhD**

Postfach 20 1180 Vienna, Austria, Tel. +43-1-71165-72085, Fax. +43-1-71165 E-mail: fifigs1@yahoo.de

Letter to the Editor

With interest we read the article by Garg et al. about a 24 years old male with sudden-onset, painless ophthalmoplegia without ataxia, areflexia, or limb weakness (acute ophthalmoparesis (AO)) who tested positive for GQ1b [1]. The patient profited from methyl-prednisolone [1]. It was concluded that AO with positive anti-GQ1b antibodies is a rare immune-mediated syndrome, which can be cost-effectively treated with steroids [1]. We have the following comments and concerns.

The main shortcoming is that the patient has not been tested for SARS-CoV-2. Though SARS-CoV-2 infected patients with OA have not been reported, several patients with Miller-Fisher syndrome (MFS) with or without affection of other cranial nerves or the limb or respiratory muscles have been published. MFS has been reported as a manifestation of neuro-COVID in a 45 years old patient who was immuno-suppressed prior to the SARS-CoV-2 infection [2]. The patient developed limb weakness after onset of MFS during the further disease course [2]. MFS as a manifestation of a SARS-CoV-2 infection was also reported in a 31 years old male with limb weakness already two months prior to onset of MFS [3]. In addition to cranial nerves VI, cranial nerves VII and XII were compromised [3]. Two other patients with cranial nerve involvement have been reported by Pascual-Goni et al. [4]. In a 36 years old male with SARS-CoV-2 associated MFS, MRI of the orbita and the retro-orbital region was notable for striking enlargement, prominent enhancement with gadolinium, and T2-hyperintensity of the left oculomotor nerve [5]. Several other COVID-19 patients with affection of cranial nerves have been published. CSF findings in patients with SARS-CoV-2 associated cranial nerve involvement is usually normal [4].

A further shortcoming is that no second spinal tap was carried out during follow-up. Cerebro-spinal fluid (CSF) protein may be normal at onset of Guillain Barre syndrome (GBS) to become elevated during the disease course [6].

Missing is a cerebral MRI to rule out Bickerstaff brainstem encephalitis (BBE) or hyperintensities of cranial nerves III, IV, and VI, as has been previously reported [5].

AO is usually preceded by infectious disease. In a study of 21 patients with AO, 17 had a history of an antecedent infection [7]. Thus, the index patient should have been tested for antibodies against campylobacter jejuni. Gastro-intestinal infections with this agent frequently precede the development of GBS. Infection with campylobacter jejunii may even go asymptomatic, why it is crucial to test patients with GBS prospectively for this agent.

GQ1b antibodies may not only be elevated in MFS but also in other subtypes of GBS, such as AO, acute ptosis, acute mydriasis, acute oropharyngeal palsy and acute ataxic neuropathy (AAN), pharyngeal-cervical-brachial (PCB) weakness, BBE, MFS/GBS overlap, and BBE/GBS overlap [8]. GQ1b antibodies are also elevated in post-infectious GQ1b antibody syndrome presenting with optic neuritis and palatal dysarthria [9].

Since cases of AO with spontaneous recovery have been reported [10], it cannot be excluded that complete recovery in the index patient was due to spontaneous recovery and not related to the application of steroids.

Overall, the presented case report is appealing but has several limitations which should be met before drawing final conclusions. Neuro-COVID needs to be excluded, follow-up CSF investigations and cerebral MRI should have been done, and antibodies against campylobacter jejuni should have been determined. Spontaneous recovery in the index patient should be considered.

References

- 1 Garg D, Vishnu VY, Singh MB, Goyal V, Padma Srivastava MV. Steroid Responsive Acute Isolated Ophthalmoplegia: A Rare Presentation of Anti-Gq1b Antibodies Syndrome. *Ann Indian Acad Neurol* 2020 Sep-Oct;23(5):739-740. doi: 10.4103/aian.AIAN_287_19.
- 2 Lowery MM, Taimur Malik M, Seemiller J, Tsai CS. Atypical Variant of Guillain Barre Syndrome in a Patient with COVID-19. *J Crit Care Med (Targu Mures)* 2020 Nov 7;6(4):231-236. doi: 10.2478/jccm-2020-0038.
- 3 Kopsic MR, Giourgas BK, Presley BC. A Case Report of Acute Motor and Sensory Polyneuropathy as the Presenting Symptom of SARS-CoV-2. *Clin Pract Cases Emerg Med* 2020 Aug;4(3):352-354. doi: 10.5811/cpcem.2020.6.48683.
- 4 Pascual-Goñi E, Fortea J, Martínez-Domeño A, Rabella N, Tecame M, Gómez-Oliva C, Querol L, Gómez-Ansón B. COVID-19-associated ophthalmoparesis and hypothalamic involvement. *Neuroimmunol Neuroinflamm* 2020 Jun 25;7(5):e823. doi: 10.1212/NXI.0000000000000823.
- 5 Lantos JE, Strauss SB, Lin E. COVID-19-Associated Miller Fisher Syndrome: MRI Findings. *AJNR Am J Neuroradiol* 2020 Jul;41(7):1184-1186. doi: 10.3174/ajnr.A6609.
- 6 Korinthenberg R. Acute polyradiculoneuritis: Guillain-Barré syndrome. *Handb Clin Neurol* 2013;112:1157-62. doi: 10.1016/B978-0-444-52910-7.00036-2.
- 7 Yuki N, Odaka M, Hirata K. Acute ophthalmoparesis (without ataxia) associated with anti-GQ1b IgG antibody: clinical features. *Ophthalmology*. 2001 Jan;108(1):196-200. doi: 10.1016/s0161-6420(00)00420-6.
- 8 de Bruyn A, Poesen K, Bossuyt X, Heremans IP, Claeys T, Depuydt CE, Van Damme P, Claeys KG. Clinical spectrum of the anti-GQ1b antibody syndrome: a case series of eight patients. *Acta Neurol Belg* 2019 Mar;119(1):29-36. doi: 10.1007/s13760-019-01093-8.
- 9 Robbins MS, Roth S, Swerdlow ML, Bieri P, Herskovitz S. Optic neuritis and palatal dysarthria as presenting features of post-infectious GQ1b antibody syndrome. *Clin Neurol Neurosurg* 2009 Jun;111(5):465-6. doi: 10.1016/j.clineuro.2008.12.005.
- 10 Kuroki S, Saida T, Nukina M, Yoshioka M, Seino J. Three patients with ophthalmoplegia associated with *Campylobacter jejuni*. *Pediatr Neurol* 2001;25:71-4.